SGLT2 Inhibitors or GLP-1 Receptor Agonists as Second-Line Therapy in Type 2 Diabetes: Patient Selection and Perspectives

Vascular Health and Risk Management
doi 10.2147/vhrm.s83088
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Combining SGLT2 Inhibitor and GLP-1 Agonist: Exaggerated Weight Loss in a Morbidly Obese Patient With Type 2 Diabetes

British Journal of Diabetes
2016English

Pdb68 - Cost-Effectiveness Analysis of Exenatide Versus GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient With Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes

Internal Medicine
Internal MedicineMedicine
2020English

Role and Development of GLP-1 Receptor Agonists in the Management of Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2009English

Combination Therapy With Once-Weekly Glucagon Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: A Case Series

Pharmacy Practice
Pharmaceutical SciencePharmacy
2019English

Evaluating Preferences for Profiles of GLP-1 Receptor Agonists Among Injection-Naïve Type 2 Diabetes Patients in the UK

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2015English

Adherence to GLP-1 Receptor Agonist Therapy Administered by Once-Daily or Once-Weekly Injection in Patients With Type 2 Diabetes in Germany

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2016English

Correction To: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults With Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

Advances in Therapy
MedicinePharmacology
2019English

Pdb112 - Treatment and Dosing Patterns Among Patients With Type 2 Diabetes (T2d) Initiating Glucagon-Like Peptide-1 Receptor Agonists (Glp-1 Ras) in Several Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy